Title | Type | SJR | H index | Total Docs. (2011) | Total Docs. (3years) | Total Refs. (2011) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2011) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Pharmacological Reviews | journal | 10.386 Q1 | 254 | 33 | 59 | 10674 | 1354 | 59 | 21.41 | 323.45 | |
2 | Critical Reviews in Therapeutic Drug Carrier Systems | journal | 1.116 Q1 | 82 | 11 | 36 | 2405 | 148 | 36 | 3.39 | 218.64 | |
3 | Medicinal Research Reviews | journal | 3.242 Q1 | 150 | 24 | 83 | 4735 | 864 | 81 | 9.73 | 197.29 | |
4 | Pharmacology and Therapeutics | journal | 3.411 Q1 | 233 | 101 | 299 | 18833 | 3024 | 296 | 9.74 | 186.47 | |
5 | Food and Drug Law Journal | journal | 0.322 Q3 | 23 | 25 | 110 | 4417 | 63 | 109 | 0.55 | 176.68 | |
6 | Advances in Pharmacology | journal | 1.058 Q1 | 86 | 30 | 73 | 4440 | 198 | 26 | 2.88 | 148.00 | |
7 | Annual Review of Pharmacology and Toxicology | journal | 10.583 Q1 | 224 | 18 | 59 | 2518 | 1415 | 59 | 24.06 | 139.89 | |
8 | Progress in Medicinal Chemistry | journal | 0.962 Q2 | 38 | 6 | 28 | 836 | 61 | 17 | 1.75 | 139.33 | |
9 | Current Molecular Pharmacology | journal | 1.689 Q1 | 49 | 18 | 64 | 2266 | 315 | 64 | 5.34 | 125.89 | |
10 | Expert Opinion on Emerging Drugs | journal | 0.973 Q2 | 54 | 45 | 135 | 5658 | 526 | 135 | 3.97 | 125.73 | |
11 | Current Medicinal Chemistry | journal | 1.699 Q1 | 202 | 430 | 828 | 53487 | 4696 | 823 | 5.48 | 124.39 | |
12 | Current Pharmaceutical Design | journal | 1.414 Q1 | 183 | 405 | 1128 | 48213 | 4871 | 1016 | 4.21 | 119.04 | |
13 | Drug Resistance Updates | journal | 4.917 Q1 | 132 | 27 | 51 | 3149 | 625 | 50 | 10.57 | 116.63 | |
14 | Current Drug Targets | journal | 1.461 Q1 | 119 | 193 | 419 | 21891 | 1600 | 379 | 3.72 | 113.42 | |
15 | CNS and Neurological Disorders - Drug Targets | journal | 1.468 Q1 | 96 | 99 | 188 | 10725 | 777 | 168 | 4.07 | 108.33 | |
16 | Current Vascular Pharmacology | journal | 0.944 Q2 | 69 | 74 | 182 | 7940 | 580 | 169 | 3.21 | 107.30 | |
17 | Side Effects of Drugs Annual | book series | 0.106 Q4 | 9 | 52 | 157 | 5441 | 4 | 53 | 0.02 | 104.63 | |
18 | Advances in Molecular Toxicology | book series | 0.191 Q3 | 18 | 7 | 24 | 718 | 14 | 20 | 0.44 | 102.57 | |
19 | Issues in Toxicology | book series | 0.160 Q4 | 18 | 14 | 79 | 1436 | 39 | 74 | 0.44 | 102.57 | |
20 | Pharmacogenomics and Personalized Medicine | journal | 0.147 Q4 | 37 | 11 | 20 | 1128 | 9 | 20 | 0.45 | 102.55 | |
21 | Current Drug Metabolism | journal | 0.993 Q1 | 122 | 98 | 277 | 10022 | 1416 | 259 | 5.17 | 102.27 | |
22 | Infectious Disorders - Drug Targets | journal | 0.778 Q2 | 61 | 48 | 131 | 4761 | 341 | 115 | 2.68 | 99.19 | |
23 | Expert Opinion on Therapeutic Targets | journal | 1.575 Q1 | 106 | 112 | 352 | 10954 | 1340 | 348 | 4.13 | 97.80 | |
24 | Current Cancer Drug Targets | journal | 2.137 Q1 | 103 | 94 | 232 | 8928 | 1118 | 220 | 4.78 | 94.98 | |
25 | Mini-Reviews in Medicinal Chemistry | journal | 0.855 Q2 | 107 | 108 | 395 | 10227 | 1177 | 393 | 2.84 | 94.69 | |
26 | Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry | journal | 0.179 Q3 | 27 | 36 | 111 | 3401 | 43 | 101 | 0.52 | 94.47 | |
27 | Cellular and Molecular Life Sciences | journal | 4.190 Q1 | 261 | 297 | 912 | 27852 | 6861 | 900 | 6.90 | 93.78 | |
28 | Neurotherapeutics | journal | 2.457 Q1 | 136 | 68 | 193 | 6372 | 1459 | 180 | 6.63 | 93.71 | |
29 | Expert Opinion on Drug Metabolism and Toxicology | journal | 1.018 Q1 | 100 | 120 | 369 | 11161 | 1500 | 365 | 3.53 | 93.01 | |
30 | Current Pharmacogenomics and Personalized Medicine | journal | 0.291 Q3 | 20 | 30 | 85 | 2789 | 112 | 75 | 1.61 | 92.97 | |
31 | Cardiovascular and Hematological Agents in Medicinal Chemistry | journal | 0.961 Q2 | 43 | 28 | 85 | 2577 | 251 | 84 | 1.96 | 92.04 | |
32 | Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry | journal | 0.126 Q4 | 17 | 33 | 93 | 3010 | 24 | 85 | 0.22 | 91.21 | |
33 | Drug Design, Development and Therapy | journal | 0.640 Q2 | 94 | 38 | 84 | 3421 | 232 | 82 | 3.11 | 90.03 | |
34 | Anti-Cancer Agents in Medicinal Chemistry | journal | 1.341 Q1 | 108 | 114 | 262 | 10207 | 950 | 234 | 3.16 | 89.54 | |
35 | Therapeutic Advances in Neurological Disorders | journal | 0.457 Q3 | 68 | 27 | 84 | 2375 | 149 | 76 | 1.98 | 87.96 | |
36 | Current Topics in Pharmacology | journal | 0.120 Q4 | 8 | 13 | 42 | 1102 | 9 | 42 | 0.23 | 84.77 | |
37 | Expert Opinion on Biological Therapy | journal | 1.312 Q1 | 102 | 141 | 459 | 11869 | 1848 | 452 | 4.34 | 84.18 | |
38 | Expert Opinion on Therapeutic Patents | journal | 1.129 Q1 | 88 | 112 | 329 | 9333 | 991 | 320 | 3.86 | 83.33 | |
39 | CNS Neuroscience and Therapeutics | journal | 1.437 Q1 | 91 | 83 | 118 | 6890 | 558 | 110 | 4.46 | 83.01 | |
40 | Inflammation and Allergy - Drug Targets | journal | 0.972 Q2 | 55 | 59 | 129 | 4860 | 480 | 124 | 3.89 | 82.37 | |
41 | International Journal for Parasitology: Drugs and Drug Resistance | journal | 47 | 4 | 0 | 327 | 0 | 0 | 0.00 | 81.75 | ||
42 | Reviews on Recent Clinical Trials | journal | 0.718 Q2 | 35 | 30 | 75 | 2410 | 171 | 74 | 2.31 | 80.33 | |
43 | Journal of Receptor, Ligand and Channel Research | journal | 0.659 Q2 | 13 | 5 | 5 | 394 | 14 | 5 | 2.80 | 78.80 | |
44 | Trends in Pharmacological Sciences | journal | 5.422 Q1 | 244 | 90 | 249 | 6986 | 2845 | 232 | 11.29 | 77.62 | |
45 | Expert Opinion on Investigational Drugs | journal | 1.541 Q1 | 117 | 142 | 487 | 11009 | 2256 | 471 | 4.88 | 77.53 | |
46 | Current Neuropharmacology | journal | 1.309 Q1 | 103 | 94 | 102 | 7032 | 445 | 97 | 3.51 | 74.81 | |
47 | Pharmacognosy Reviews (discontinued) | journal | 0.355 Q3 | 68 | 23 | 70 | 1716 | 105 | 70 | 1.50 | 74.61 | |
48 | Expert Opinion on Pharmacotherapy | journal | 0.800 Q2 | 93 | 259 | 847 | 18824 | 2415 | 814 | 2.99 | 72.68 | |
49 | Expert Review of Vaccines | journal | 1.405 Q1 | 105 | 167 | 435 | 11738 | 1689 | 350 | 3.91 | 70.29 | |
50 | Neuropsychopharmacology | journal | 4.150 Q1 | 249 | 254 | 807 | 17601 | 6542 | 771 | 7.85 | 69.30 |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®